Larimar Therapeutics to Participate in Upcoming Investor Conferences

8/27/24 8:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $LRMR alert in real time by email

BALA CYNWYD, Pa., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company's management team will participate in 1x1 investor meetings at the Wells Fargo Healthcare Conference, taking place September 4-6, 2024 in Boston, MA and the H.C. Wainwright 26th Annual Global Investment Conference, taking place September 9-11, 2024 in New York, NY.

About Larimar Therapeutics

Larimar Therapeutics, Inc. (NASDAQ:LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar's lead compound, nomlabofusp, is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.

Investor Contact:

Joyce Allaire

LifeSci Advisors

[email protected]

(212) 915-2569

Company Contact:

Michael Celano

Chief Financial Officer

[email protected]

(484) 414-2715

Get the next $LRMR alert in real time by email

Date	Price Target	Rating	Analyst
10/16/2024	$26.00	Outperform	Oppenheimer
10/3/2024	$22.00	Outperform	Wedbush
10/2/2024	$15.00	Buy	H.C. Wainwright
9/4/2024	$16.00	Outperform	Robert W. Baird
4/3/2024	$25.00	Outperform	Leerink Partners
11/17/2023	$4.50	Neutral → Buy	Citigroup
10/19/2022	$12.00	Buy	Guggenheim
2/15/2022		Outperform → Market Perform	William Blair

Larimar Therapeutics to Participate in Upcoming Investor Conferences

Chat with this insight

Recent Analyst Ratings for $LRMR

$LRMR Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Flynn James E

SEC Form 4 filed by Thomas Frank E

SEC Form 4 filed by Leff Jonathan S

$LRMR Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Larimar Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Larimar Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Larimar Therapeutics Inc.

$LRMR Press Releases

Fastest customizable press release news feed in the world

$LRMR Financials

Live finance-specific insights

$LRMR Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Larimar Therapeutics Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024

Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results

Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research

Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich's Ataxia

Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601's Phase 2 Friedreich's Ataxia Trial and to Initiate Open Label Extension Trial

Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trial's 25 mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreich's Ataxia and First Quarter 2023 Financial Results

Oppenheimer initiated coverage on Larimar Therapeutics with a new price target

Wedbush initiated coverage on Larimar Therapeutics with a new price target

H.C. Wainwright initiated coverage on Larimar Therapeutics with a new price target

$LRMR Market Insights

Live Market Insights

Why Helen of Troy Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Nvidia, Micron, Arlo Technologies And Other Big Stocks Moving Higher On Tuesday

Worthington Enterprises Posts Downbeat Results, Joins Taysha Gene Therapies, General Mills And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

$LRMR Leadership Updates

Live Leadership Updates

$LRMR SEC Filings

Larimar Therapeutics Appoints Dr. Jeffery W. Sherman to its Board of Directors

Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results

Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer

Larimar Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

SEC Form 10-Q filed by Larimar Therapeutics Inc.

Larimar Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

$LRMR Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Hamilton Thomas Edward bought $499,998 worth of shares (57,208 units at $8.74), increasing direct ownership by 11% to 564,798 units (SEC Form 4)

Flynn James E bought $37,499,993 worth of shares (4,290,617 units at $8.74) (SEC Form 4)

Thomas Frank E bought $22,000 worth of shares (2,000 units at $11.00) (SEC Form 4)

Recent Analyst Ratings for
$LRMR

$LRMR
Insider Trading

$LRMR
Large Ownership Changes

$LRMR
Press Releases

$LRMR
Financials

$LRMR
Analyst Ratings

$LRMR
Market Insights

$LRMR
Leadership Updates

$LRMR
SEC Filings

$LRMR
Insider Purchases